Arbiter 6 -- Early Returns From The US Prescription Data Aggregators

Courtesy Marilyn Mann, from a CNN article, of yesterday afternoon:
. . . .Niaspan prescriptions between new patients who hadn't taken any cholesterol drug in a prior twelve months rose 33.8% from a prior week, whilst prescriptions upon that basement for Zetia forsaken 24% as well as were down 16.8% for Vytorin. New Niaspan prescriptions between people who had taken a different cholesterol drug in a prior twelve months rose 45.6% from a week before, whilst Zetia declined 27.4% as well as Vytorin forsaken 23.7% upon identical bases.

Merck orator Ron Rogers said a association isn't informed with a SDI data, as well as that it would be "premature" to sign a impact of a Arbiter 6 investigate upon market trends. . . .